Cover Image
市場調查報告書

纖維母細胞生長因子受體2:開發中產品分析

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365770
出版日期 內容資訊 英文 136 Pages
訂單完成後即時交付
價格
Back to Top
纖維母細胞生長因子受體2:開發中產品分析 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 136 Pages
簡介

本報告提供以纖維母細胞生長因子受體2為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

纖維母細胞生長因子受體2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Advenchen Laboratories, LLC
  • Amgen Inc.
  • ArQule, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Batu Biologics, Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celon Pharma Sp. z o.o.
  • 第一三共
  • Debiopharm International SA
  • Eddingpharm
  • Eisai
  • Eli Lilly and Company
  • Hutchison MediPharma Limited
  • Incyte Corporation
  • Johnson & Johnson
  • 科研製藥
  • Les Laboratoires Servier SAS
  • Nobelpharma Co., Ltd.
  • Novartis AG
  • Principia Biopharma Inc.
  • Vichem Chemie Research Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0224TDB

Summary

Global Markets Direct's, 'Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)
  • The report reviews Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) Overview
  • Therapeutics Development
    • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Stage of Development
    • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Therapy Area
    • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Indication
  • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Companies
  • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Universities/Institutes
  • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • Advenchen Laboratories, LLC
    • Amgen Inc.
    • ArQule, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • AVEO Pharmaceuticals, Inc.
    • Batu Biologics, Inc.
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Celon Pharma Sp. z o.o.
    • Daiichi Sankyo Company, Limited
    • Debiopharm International SA
    • Eddingpharm
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Hutchison MediPharma Limited
    • Incyte Corporation
    • Johnson & Johnson
    • Kaken Pharmaceutical Co., Ltd.
    • Les Laboratoires Servier SAS
    • Nobelpharma Co., Ltd.
    • Novartis AG
    • Principia Biopharma Inc.
    • Vichem Chemie Research Ltd.
  • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Drug Profiles
    • ARQ-087 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-5878 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-4547 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1163877 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1179470 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1187982 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986036 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPL-043 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Debio-1347 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-1123 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-7090 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDP-317 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erdafitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GP-369 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMPL-453 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-54828 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • infigratinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-27 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenvatinib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lucitanib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-2874455 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nintedanib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palifermin (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRN-1371 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPT-835 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-49076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trafermin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trafermin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vallovax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Dormant Projects
  • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Discontinued Products
  • Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Featured News & Press Releases
    • Jun 06, 2016: Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology Annual Meeting
    • May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology
    • May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma
    • May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis
    • May 09, 2016: LUME-Meso trial enrols first patient: Boehringer Ingelheim's new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma
    • Apr 20, 2016: Eisai Announces Non-Clinical Research Findings At Aacr 107Th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus
    • Apr 15, 2016: Debiopharm International announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor
    • Apr 12, 2016: Highly Anticipated New Treatment Option Now Available for Canadians with Select Type of Thyroid Cancer
    • Mar 09, 2016: Lenvima (lenvatinib) Now Available in Israel as Important New Treatment for People with Advanced Thyroid Cancer
    • Mar 03, 2016: Batu Biologics Recruits Diagnostics Expert to Oversee Precision-Medicine Company Arm
    • Feb 25, 2016: Eisai Slams the New Cancer Drug Fund that Further Delays Patient Access to New Cancer Drug
    • Feb 25, 2016: New analysis confirms OFEV (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
    • Jan 27, 2016: NICE recommends nintedanib for idiopathic pulmonary fibrosis
    • Jan 26, 2016: Boehringer Ingelheim is Pleased to Welcome Green Light from the National Institute for Health and Care Excellence (NICE) for Its Medicine for Rare Lung Disease
    • Jan 18, 2016: U.S. FDA Accepts For Priority Review sNDA For Eisai'S Anticancer Agent Lenvatinib Seeking Approval For Renal Cell Carcinoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Pipeline by Amgen Inc., H1 2016
  • Pipeline by ArQule, Inc., H1 2016
  • Pipeline by Astellas Pharma Inc., H1 2016
  • Pipeline by AstraZeneca Plc, H1 2016
  • Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Pipeline by Batu Biologics, Inc., H1 2016
  • Pipeline by Bayer AG, H1 2016
  • Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pipeline by Celon Pharma Sp. z o.o., H1 2016
  • Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Pipeline by Debiopharm International SA, H1 2016
  • Pipeline by Eddingpharm, H1 2016
  • Pipeline by Eisai Co., Ltd., H1 2016
  • Pipeline by Eli Lilly and Company, H1 2016
  • Pipeline by Hutchison MediPharma Limited, H1 2016
  • Pipeline by Incyte Corporation, H1 2016
  • Pipeline by Johnson & Johnson, H1 2016
  • Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016
  • Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Pipeline by Nobelpharma Co., Ltd., H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by Principia Biopharma Inc., H1 2016
  • Pipeline by Vichem Chemie Research Ltd., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Discontinued Products, H1 2016
  • Discontinued Products (Contd..1), H1 2016
  • Discontinued Products (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top